Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.
about
Classic tumor markers in gastric cancer. Current standards and limitationsThe clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updatesPotential prognostic, diagnostic and therapeutic markers for human gastric cancerGenetics and biological markers in urachal cancerCancer/testis antigens, gametogenesis and cancerIntegrative network analysis of TCGA data for ovarian cancer.Novel strategies for managing pancreatic cancer.Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.Biology and management of pancreatic cancer.Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.Elevated serum CA72-4 levels predict poor prognosis in pancreatic adenocarcinoma after intensity-modulated radiation therapy.Evaluation of matrix metalloproteinase 7 in plasma and pancreatic juice as a biomarker for pancreatic cancer.A single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer.Prognostic factors in patients with pancreatic cancerPancreatic cancer screeningDiagnostic management of pancreatic cancer.Aberrant glycosylation as biomarker for cancer: focus on CD43.CDX-1307: a novel vaccine under study as treatment for muscle-invasive bladder cancer.Prognostic factors related with survival in patients with pancreatic adenocarcinomaIntegrated expression profiles analysis reveals novel predictive biomarker in pancreatic ductal adenocarcinoma.Diagnostic value of biochemical biomarkers in malignant and non-malignant pericardial effusion.Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer.Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
P2860
Q26777296-511EB9FD-0ACB-4755-9B8D-54D722A67B01Q26865015-A172D816-E00A-4C9B-B318-E34A0972AFFFQ26866200-B9DD6FBC-D36D-40CD-9E44-78A9F34DAF00Q28069688-306EB061-5AA8-4BDE-A17E-5D76A3BAD322Q29616129-0179B9B0-0D07-44EF-B294-D8B5F68F1D9EQ30882404-3375F9E1-EA4D-44E3-998C-A8B42DA113FBQ34405057-809CA75E-369E-4704-9009-4D8A7172AA0BQ34635042-F7851BA8-C03B-49A4-A733-0784C13E8EE8Q34649019-B3FAAFA1-9C69-4284-AD85-9AAC20BFE981Q35152701-521E3EA5-F345-4951-9CA9-6BE15B620345Q35832454-8FB23055-B79E-442E-B8D1-65D84D623929Q35892368-53B4191C-A203-48C1-AAAF-CEBE4F5A7F64Q35911669-B676D500-A522-4076-B076-619B42CAE0F5Q36224397-882AB343-0AC1-47A3-B960-5471D9A07AD5Q36896536-B987AEC6-E9CA-4DF7-9527-161339216543Q37129792-2DE24E8E-5424-4D76-8DCF-5F8747F5B723Q37618865-AD0FE452-B123-4CCE-8331-933A3A52A610Q37892578-CAF6006D-655F-419A-9A56-D21AC329F639Q38242807-5E7225F4-1FD7-40AE-9647-045F43B9A10AQ41592795-D6B98612-B069-4864-85EB-1B9CA45805AFQ44257074-F8CE713C-ADF3-4D9D-9DFC-C1046CFD8CF9Q50579768-503C28B1-A07F-4208-804F-C3227C7F9E9BQ51697993-D8F979AF-4DDF-41AB-9543-EFAC98F3DF7F
P2860
Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Serum HCG beta and CA 72-4 are ...... d CA 242 in pancreatic cancer.
@ast
Serum HCG beta and CA 72-4 are ...... d CA 242 in pancreatic cancer.
@en
Serum HCG beta and CA 72-4 are ...... d CA 242 in pancreatic cancer.
@nl
type
label
Serum HCG beta and CA 72-4 are ...... d CA 242 in pancreatic cancer.
@ast
Serum HCG beta and CA 72-4 are ...... d CA 242 in pancreatic cancer.
@en
Serum HCG beta and CA 72-4 are ...... d CA 242 in pancreatic cancer.
@nl
prefLabel
Serum HCG beta and CA 72-4 are ...... d CA 242 in pancreatic cancer.
@ast
Serum HCG beta and CA 72-4 are ...... d CA 242 in pancreatic cancer.
@en
Serum HCG beta and CA 72-4 are ...... d CA 242 in pancreatic cancer.
@nl
P2093
P356
P1433
P1476
Serum HCG beta and CA 72-4 are ...... d CA 242 in pancreatic cancer.
@en
P2093
Caj Haglund
Henrik Alfthan
Johanna Louhimo
P304
P356
10.1159/000077438
P577
2004-01-01T00:00:00Z